Loading articles...
MASH (metabolic dysfunction-associated steatohepatitis) is a complex disease, and while we've made strides, key mechanistic details remain elusive. This demands a sharper focus on translational studies that can directly inform clinical practice.
Patients on lorlatinib require vigilant monitoring for hyperglycemia and ketoacidosis, regardless of pre-existing diabetes risk factors. Proactive screening and early intervention are crucial to mitigate potential severe complications and ensure patient saf...
Patients on lorlatinib may develop diabetes with unusual characteristics, including the absence of typical autoantibodies. This presents a diagnostic challenge, requiring clinicians to consider drug-induced etiologies even when initial immunological markers...
A new review in Nature Reviews Gastroenterology & Hepatology clarifies the complex interplay of metabolism, inflammation, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This understanding translates to practical guidance for risk s...
SGLT2 inhibitors show potential for managing glycemic control in Prader-Willi Syndrome, but clinicians must be vigilant about the risk of renal complications. This necessitates careful patient selection and close monitoring of kidney function throughout tre...
Using cranial CT scans for opportunistic osteoporosis screening shows promise, but concerns remain. Addressing methodological criticisms is essential for validating this approach in broader clinical practice.
Youth-onset type 2 diabetes (T2D) poses unique challenges, and this study sheds light on how common treatments like metformin and liraglutide impact the gut microbiome. Understanding these shifts may allow for more targeted therapies and improved outcomes i...
Opportunistic osteoporosis screening using cranial CT scans could identify patients at high risk of major osteoporotic fractures without additional radiation. But workflow integration and cost-effectiveness remain open questions.
Patients with Prader-Willi Syndrome (PWS) face unique metabolic challenges; SGLT2 inhibitors may offer some benefit, but careful monitoring is essential. This analysis highlights the need for rigorous trials to define the risk-benefit profile of SGLT2 inhib...
Patients with Prader-Willi Syndrome (PWS) present unique challenges when considering SGLT2 inhibitors due to their metabolic and behavioral complexities. Vigilant monitoring for euglycemic DKA and proactive management of dehydration risks are paramount when...